| Literature DB >> 23295105 |
Juha Sinnemäki1, Sinikka Sihvo, Jaana Isojärvi, Marja Blom, Marja Airaksinen, Antti Mäntylä.
Abstract
BACKGROUND: An automated dose dispensing (ADD) service has been implemented in primary healthcare in some European countries. In this service, regularly used medicines are machine-packed into unit-dose bags for each time of administration. The aim of this study is to review the evidence for ADD's influence on the appropriateness of medication use, medication safety, and costs in primary healthcare.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23295105 PMCID: PMC3598731 DOI: 10.1186/2046-4053-2-1
Source DB: PubMed Journal: Syst Rev ISSN: 2046-4053
Search strategy for the medline
| 1 | automated medication dispens*.ti,ab. (20) |
| 2 | automated medication distribut*.ti,ab. (6) |
| 3 | automated drug distribut*.ti,ab. (5) |
| 4 | automated drug dispens*.ti,ab. (14) |
| 5 | automated dose-dispens*.ti,ab. (3) |
| 6 | automated dose distribut*.ti,ab. (0) |
| 7 | automated dispensing system*.ti,ab. (29) |
| 8 | multidose drug dispens*.ti,ab. (0) |
| 9 | multi-dose drug dispens*.ti,ab. (2) |
| 10 | multidose drug distribut*.ti,ab. (1) |
| 11 | multi-dose drug distribut*.ti,ab. (1) |
| 12 | unit-dose dispens*.ti,ab. (45) |
| 13 | unit-dose distribut*.ti,ab. (33) |
| 14 | (automat* adj2 (dispens* or distribut*) adj2 (device* or system* or scheme*)).ti,ab. (96) |
| 15 | (automat* adj2 dose dispens*).ti,ab. (7) |
| 16 | (automat* adj2 dose distribut*).ti,ab. (10) |
| 17 | ((multidose or multi-dose) adj2 dispens*).ti,ab. (8) |
| 18 | ((multidose or multi-dose) adj2 distribut*).ti,ab. (5) |
| 19 | (unit-dose adj2 (dispens* or distribut*)).ti,ab. (218) |
| 20 | or/1-19 (350) |
| 21 | (news or letter or comment or editorial or interview or historical article).pt. (1438428) |
| 22 | 20 not 21 (338) |
| 23 | limit 22 to yr=”1995-current |
Description and results of the studies on automated dose dispensing (ADD) in primary healthcare
| Sjöberg et al.
[ | To compare changes in drug treatments within and outside ADD | Level 2 | 154 community-dwelling or nursing home residents ≥65 years of age (patients using ADD n = 107, not using ADD n = 47). Data on drug treatments were extracted from the medical records (t = 0 months) and from the SPDR (t = 6 months). A multi-level analysis was performed, with drugs at the first level and individuals at the second. | Number of changed (withdrawn, dosage adjusted, or newly prescribed) and not changed drugs. | |
| Controlled register study | | | | | The risk of medication to be classified as unchanged was higher among ADD users (OR 1.66, 95% CI 1.20-2.31, adjusted for age, sex, cognition, year of data collection, subgroup of drug). |
| Sjöberg et al.
[ | To investigate association between ADD and quality of drug treatment | Level 3 | All community-dwelling or nursing home residents from Västra Götaland ≥65 years of age in late 2007 and having ≥2 health care visits and ≥2 diagnosis in 2005–2007. Study group: ADD users (n = 4927). Control group: patients not using ADD (n = 19 219). Data were collected from the SPDR in 2007 linked with register data on patient diagnoses and residence. | Five quality indicators for potential IDU: | |
| Controlled cross-sectional register study | | | | 1. Use of ≥10 drugs | ADD users had a higher prevalence of all indicators of potential IDU (5.9-55.1%) than the control population (2.6-4.9%) ( |
| | | | | 2. Use of long-acting benzodiazepines | |
| | | | | 3. Use of anticholinergic drugs | |
| | | | | 4. Use of ≥3 psychotropic drugs | |
| | | | | 5. Potential DDIs | |
| Wekre et al.
[ | Impact of ADD on inconsistencies in medication records between GPs and home care services | Level 3 | A convenience sample of 59 patients. Medication records were collected 0.5 years before and 1 year after the ADD implementation. | Number of discrepancies between the patients’ medication records at the GPs and at the home care services | |
| | | | | | ADD did not change the number of medication records with discrepancies (before 47 and after 45 out of 59, |
| Controlled before-after study | | | | | |
| Johnell and Fastbom
[ | Whether the use of ADD is associated with potential IDU | Level 2 | All Swedes ≥75 years of age who were registered in SPDR. Study group: ADD users (n = 122 413). Control group: patients not using ADD (n = 608, 692). Data were collected from the SPDR in 2005. | Four quality indicators for potential IDU: | |
| | | | | | ADD users had a higher prevalence of all indicators of potential IDU (8.8-22.1%) than the control population (2.4-4.9%). |
| Controlled cross-sectional register study | | | | 1. use of long-acting benzodiazepines | |
| | | | | 2. use of anticholinergic drugs | After adjustment for age and number of dispensed drugs, risk of using any IDU, anticholinergic drugs and ≥3 psychotropic drugs were higher among ADD users (ORs 1.43-4.93; 95% CI 1.40-5.17). Contrasting relationship prevailed for long-acting benzodiazepines among women and potentially serious DDIs among women and men (ORs 0.69-0.80; 95% CI 0.66-0.83). |
| | | | | 3. use of ≥3 psychotropic drugs | |
| | | | | 4. potential DDIs | |
| Olsson et al.
[ | Extent and quality of drug prescribing in younger elderly (65–79 years) and older elderly (≥80 years) receiving ADD | ADD is mentioned but no description is given. | All residents of nursing homes and dementia special care units ≥65 years of age (n = 3705) from the County of Jönköping. Data on prescribed drugs were collected from the national pharmacy drug register. | Five quality indicators for potential IDU: | |
| Cross-sectional register study | | | | 1. Use of long-acting benzodiazepines | Influence of ADD on potential IDU not studied. Potential IDU prevalences ranged from 7.6% to 41.2%. Prevalences of potential IDU were mainly higher among younger (65–79 years) than older (≥80 years) residents (not statistically tested). |
| | | | | 2. Use of anticholinergic drugs | |
| | | | | 3. drug duplications | |
| | | | | 4. Use of ≥3 psychotropic drugs | |
| | | | | 5. Potential DDIs | |
| van den Bemt et al.
[ | Frequency of medication administration errors and potential risk factors for these errors in nursing homes using ADD | Level 2 | In all, 2025 administrations to 127 residents of three nursing homes were observed by one pharmacy technician. | Medication administration error rates | |
| | | | | | Administration error rate for all administered medications observed (via ADD and without ADD) was 21.2% (n = 428 errors). Most common error type was wrong administration technique (n = 312). The risk for administration errors was higher when medicine was not supplied by ADD (OR 2.92; 95% CI 2.04-4.18). |
| Prospective observational study | | | | | |
| Bergman et al.
[ | Quality of drug therapy among nursing home residents using ADD | Level 1 | All nursing home residents ≥65 years of age (n = 7904) from Gothenburg area. Data were collected from the Swedish national drug register for ADD users. | Five quality indicators for potential IDU: | |
| Cross-sectional register study | | | | 1. use of long-acting benzodiazepines | Influence of ADD on potential IDU not studied. Potential IDU prevalences ranged from 12.1% to 45.2%. The proportion of potential IDU was higher among 65–79 year-old residents than those ≥80 years old ( |
| | | | | 2. Use of anticholinergic drugs | |
| | | | | 3. Drug duplications | |
| | | | | 4. Use of ≥3 psychotropic drugs | |
| 5. Potential DDIs | |||||
ADD, Automated dose dispensing; DDI, Drug-drug interaction; GP, General practitioner; IDU, Inappropriate drug use; n.s., Not significant; SPDR, Swedish Prescribed Drug Register.
Levels of description: Level 1: Drugs are machine-packed into unit-dose bags. One unit-dose bag contains all the tablets that are administered to a patient at the same time; Level 2: In addition to level 1, each bag has a label with the following information: patient’s name, the name(s) of the medication(s), and the date and time of administration; Level 3: In addition to levels 1 and 2, a medication record was set up.
Figure 1Flow chart of the study selection process.